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In 2016, a global shortage of yellow fever vaccine occurred as a result of major yellow fever out­breaks in Angola and the Democratic Republic of 
Congo (DRC). By October, 7136 cases and 493 deaths 
were reported in the two countries. 
Reactive vaccination campaigns 
were conducted in areas with auto­
chthonous transmission during 
the summer of 2016, but many 
people were still living in areas 
of risk. In Kinshasa, the capital of 
the DRC, a preventive campaign 
targeting roughly 10.5 million 
people was needed to mitigate 
the risk of an urban yellow fever 
outbreak. However, only 5.8 mil­
lion vaccine doses were available 
from the World Health Organiza­
tion (WHO) stockpile. A solution 
was urgently needed.
Fractionating the available yel­
low fever vaccine doses and ad­
ministering a reduced volume of 
vaccine was one proposal. Faced 
with the options of using off­label 
fractional­dose vaccine to meet 
the supply needs or using the 
full­dose vaccine but leaving mil­
lions of people at risk for yellow 
fever, the DRC, in close consulta­
tion with the WHO, opted to use 
one fifth of the standard 0.5 ml 
volume of vaccine (0.1 ml) in its 
vaccination campaign. More than 
7 million people received the 
fractional­dose vaccine in Kinshasa 
in August 2016.
This decision was based on 
simple math. WHO­prequalified 
yellow fever vaccines are highly 
potent, with average doses be­
tween 12,874 and 43,651 interna­
tional units (IU) — far above the 
WHO’s recommended minimum 
of 1000 IU. In principle, the quan­
tity of vaccine virus in fractional 
doses of standard vaccine would 
therefore still exceed the WHO’s 
minimum requirement.
But fractionating yellow fever 
vaccine doses is not without com­
plexity. Average doses vary sub­
stantially among vaccine manu­
facturers and among product 
batches from a given manufac­
turer. Fractionating doses from 
vaccine vials at the lower end of 
the dosage range could result in 
doses close to or below the WHO 
minimum. Furthermore, potency 
can wane when vaccines are near­
ing the end of their shelf life, 
which for WHO­prequalified yel­
low fever vaccines is 36 months. 
Even the WHO’s recommended 
minimum dose must be regarded 
with some caution, since it is 
based on studies in animals rather 
than rigorous dose­finding studies 
in humans. Thus, it is important to 
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ensure that the immunogenicity 
of fractional doses is equivalent to 
that of standard doses of current­
ly used vaccines.
At the time of the 2016 out­
break, there were three publica­
tions from two studies on the 
safety and immunogenicity of 
fractional­dose yellow fever vac­
cine administered through the rec­
ommended route (intramuscular 
or subcutaneous). Since the older 
study was based on a vaccine for­
mulation no longer in use, the 
primary study that informed the 
WHO recommendations was a 
dose–response study conducted 
in Brazil in 2009, using a vaccine 
produced by Bio­Manguinhos.1 In 
that study, 900 men were ran­
domly assigned to receive one of 
six de­escalating doses of the 
17DD yellow fever vaccine, rang­
ing from 27,476 to 31 IU. Thirty 
days after vaccination, seroconver­
sion rates were 97 to 99% for 
vaccine doses of 587 IU or high­
er. Among people who originally 
seroconverted, more than 97% of 
those who received vaccine doses 
of 158 IU or higher still had detect­
able antibodies roughly 10 months 
after vaccination. An analysis of 
the cellular immune response 
showed equivalence to the full 
dose down to the tested dose of 
3013 IU, but not at doses of 587 IU 
or lower.2 Although these data 
were considered reassuring, they 
were restricted to a single coun­
try, manufacturer, and population 
(male adults).
In the context of the emergency 
situation and vaccine shortage, 
the WHO considered these data 
sufficient to proceed with a frac­
tional­dose vaccination campaign. 
Full­dose vaccination was still 
recommended for young children 
and pregnant women.
The WHO published its offi­
cial position on fractional­dose 
yellow fever vaccination in June 
2017. The agency recommends 
fractional­dose vaccination during 
a yellow fever outbreak only if 
there is a shortage of full­dose 
vaccine and emergency­response 
needs exceed the capacity of the 
global stockpile. Furthermore, it 
is still recommended that some 
groups, such as children less 
than 2 years of age and pregnant 
women, receive the full­dose vac­
cine, given the lack of data dem­
onstrating the safety and immu­
nogenicity of fractional doses. 
Because of limited data on dura­
tion of protection, fractional­dose 
vaccination also does not qualify 
people for international travel un­
der the International Health Reg­
ulations, a document signed by 
196 countries to help the inter­
national community prevent and 
respond to acute public health 
risks. Without assurances that a 
fractional­dose vaccine provides 
the same lifetime protection as a 
full­dose vaccine, people who re­
ceive fractional doses will need to 
be revaccinated before traveling 
to countries where yellow fever is 
endemic and where the Interna­
tional Health Regulations require 
proof of vaccination.
In light of important knowledge 
gaps related to fractional­dose vac­
cination, the WHO developed a 
research agenda to stimulate sci­
entists, policymakers, funders, and 
industry to address policy­relevant 
research questions (see box). The 
global community immediately re­
sponded. A small observational 
study conducted during the Au­
gust 2016 fractional­dose yellow 
fever vaccination campaign in the 
DRC demonstrated 98% serocon­
version among people who were 
seronegative at the time of vac­
cination.3 Participants from the 
dose­finding study by Bio­Man­
guinhos1 were reexamined to as­
sess long­term immunogenicity: of 
318 participants who seroconvert­
ed after vaccination in the origi­
nal study, 85% were still seroposi­
tive 8 years later.4 A randomized 
noninferiority trial was recently 
launched comparing seroconver­
sion after fractional­dose and 
full­dose yellow fever vaccination 
for each WHO­prequalified vaccine 
product (ClinicalTrials.gov number, 
NCT02991495). This study will 
evaluate fractional­dose vaccination 
in adults living with HIV and in 
children. Other studies are exam­
ining the immunogenicity of frac­
tional­dose vaccines in children, 
using various fractional volumes 
and routes of administration.
Are all WHO‑prequalified yellow fever vaccines suitable for fractional‑dose vaccina‑
tion on the basis of immunogenicity, safety, and programmatic considerations?
Is fractional‑dose vaccination sufficiently immunogenic in children 9 months to  
2 years of age?
Are immunogenicity and vaccine effectiveness 5 or more years after vaccination 
 affected by the fractional dose?
Are immune responses to fractional‑dose yellow fever vaccination similar in popula‑
tions with variable environmental exposures (e.g., exposure to other flaviviruses 
or flavivirus vaccination) and genetic backgrounds?
Is fractional‑dose vaccination sufficiently immunogenic in people with asymptom‑
atic HIV infection?
Does the incidence of severe adverse events after vaccination with fractional‑dose 
yellow fever vaccine differ from that with standard‑dose vaccine?
Research Questions to Support Near-Term Policy Recommendations  
for Fractional-Dose Yellow Fever Vaccination.
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Use of fractional­dose vacci­
nation in mass vaccination cam­
paigns presents an opportunity to 
compare the safety of fractional­
dose and full­dose yellow fever 
vaccines — particularly rates of 
rare, serious adverse events such 
as vaccine­associated neurotropic 
and viscerotropic disease. Prelim­
inary data from routine safety 
monitoring during campaigns in­
volving more than 5 million peo­
ple in Brazil who received a frac­
tional­dose vaccine are reassuring.
The 2016 outbreak in central 
and southern Africa was a re­
minder of the delicate supply­
and­demand situation for yellow 
fever vaccines. Beyond the WHO 
vaccine stockpile, there is limited 
capacity to respond to demand 
peaks during larger outbreaks. 
Limited market incentives and a 
long manufacturing process re­
quiring embryonated chicken eggs 
have created barriers to market 
entry and manufacturing surge 
capacity.
Recently, another vaccine short­
age has prompted fractional­dose 
vaccination campaigns in large 
cities in Brazil, including areas 
not previously recognized as be­
ing at risk for yellow fever and 
thus with largely susceptible 
populations. Although the yellow 
fever vaccine stockpile is in place 
to address peaks in demand, it is 
less suited to cover the surge ca­
pacity needed for major urban 
vaccination campaigns. During 
the 2016 outbreak, the stockpile 
was depleted three times. Com­
pounding this problem is the 
fact that global vaccine coverage 
is well below the 80% target that 
is expected to maintain a suffi­
ciently high level of population 
immunity to eliminate outbreak 
risk: a recent study estimated 
that at least 393.7 million people 
living in high­risk settings (43%) 
remain unvaccinated.5 Interna­
tional air travel may introduce 
yellow fever virus to new cities 
suitable for transmission. The best 
defense against future vaccine 
shortages is to achieve adequate 
routine vaccine coverage in all 
affected areas.
Other countries have consid­
ered a broader application of 
fractional­dose yellow fever vac­
cination outside emergency short­
ages. However, core questions re­
main. Although available evidence 
supports the use of fractional­
dose vaccination when needed, a 
larger evidence base will be im­
portant to ensure optimal use 
and protection. Ongoing studies 
will provide much­needed infor­
mation about specific products, 
target populations, and duration 
of protection to strengthen vac­
cination policies.
Continued dialogue and coor­
dination among the policy, re­
search, and funding communi­
ties are critical to ensure that 
when public health emergencies 
arise, there is sufficient evidence 
to make robust policy decisions 
quickly. Policy­driven research 
agendas are important tools for 
facilitating such coordination.
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